

## Crk II Monoclonal Antibody


<b>Catalog No :</b>	YM1024
<b>Reactivity :</b>	Human;Mouse;Dog;Rabbit
<b>Applications :</b>	WB
<b>Target :</b>	Crk II
<b>Fields :</b>	>>MAPK signaling pathway;>>ErbB signaling pathway;>>Rap1 signaling pathway;>>Chemokine signaling pathway;>>Focal adhesion;>>Fc gamma R-mediated phagocytosis;>>Neurotrophin signaling pathway;>>Regulation of actin cytoskeleton;>>Insulin signaling pathway;>>Growth hormone synthesis, secretion and action;>>Bacterial invasion of epithelial cells;>>Shigellosis;>>Yersinia infection;>>Human cytomegalovirus infection;>>Human immunodeficiency virus 1 infection;>>Pathways in cancer;>>MicroRNAs in cancer;>>Renal cell carcinoma;>>Chronic myeloid leukemia
<b>Gene Name :</b>	CRK
<b>Protein Name :</b>	Adapter molecule crk
<b>Human Gene Id :</b>	1398
<b>Human Swiss Prot No :</b>	P46108
<b>Mouse Gene Id :</b>	12928
<b>Mouse Swiss Prot No :</b>	Q64010
<b>Rat Swiss Prot No :</b>	Q63768
<b>Immunogen :</b>	Purified recombinant human Crk II protein fragments expressed in E.coli.
<b>Specificity :</b>	Crk II Monoclonal Antibody detects endogenous levels of Crk II protein.
<b>Formulation :</b>	Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
<b>Source :</b>	Monoclonal, Mouse

<b>Dilution :</b>	WB 1:1000 - 1:2000. Not yet tested in other applications.
<b>Purification :</b>	Affinity purification
<b>Concentration :</b>	1 mg/ml
<b>Storage Stability :</b>	-15°C to -25°C/1 year(Do not lower than -25°C)
<b>Molecularweight :</b>	34kD
<b>Cell Pathway :</b>	MAPK_ERK_Growth;MAPK_G_Protein;ErbB_HER;Chemokine;Focal adhesion;Fc gamma R-mediated phagocytosis;Neurotrophin;Regulates Actin and Cytoskeleton;Insulin_Receptor;Pathways in cancer;Renal cell carcinoma
<b>Background :</b>	<p>This gene encodes a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. The product of this gene has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation. Two alternative transcripts encoding different isoforms with distinct biological activity have been described. [provided by RefSeq, Jul 2008],</p>
<b>Function :</b>	<p>domain:The C-terminal SH3 domain function as a negative modulator for transformation and the N-terminal SH3 domain appears to function as a positive regulator for transformation.,domain:The SH2 domain mediates interaction with SHB.,function:The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk-II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4.,PTM:Phosphorylated on Tyr-221 upon cell adhesion. Results in the negative regulation of the association with SH2- and SH3-binding partners, possibly by the formation of an intramolecular interaction of phosphorylated Tyr-221 with the SH2 domain. This leads finally to the down-regulation of the Crk signaling pathway.,PTM:P</p>
<b>Subcellular Location :</b>	Cytoplasm . Cell membrane . Translocated to the plasma membrane upon cell adhesion. .
<b>Expression :</b>	Embryonic lung,Epithelium,Eye,Lung,Placenta,
<b>Sort :</b>	4571
<b>No4 :</b>	1

**Host :** Mouse

**Modifications :** Unmodified

## Products Images



Western Blot analysis using Crk II Monoclonal Antibody against LNCAP, A431, MCF7, HL1080 cell lysate.